within Pharmacolibrary.Drugs.ATC.M;

model M03BX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.0005383333333333333,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.105,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016833333333333332,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M03BX09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Eperisone is a centrally acting muscle relaxant used primarily for the treatment of muscle spasticity and related musculoskeletal disorders. It acts by inhibiting both spinal and supraspinal reflexes and offers vasodilatory effects. Eperisone is available in some Asian countries, such as Japan and India, but is not approved in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult Japanese volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Baek, IH, et al., &amp; Kim, MS (2021). Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. <i>Biopharmaceutics &amp; drug disposition</i> 42(2-3) 94–102. DOI:<a href=\"https://doi.org/10.1002/bdd.2264\">10.1002/bdd.2264</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33527395/\">https://pubmed.ncbi.nlm.nih.gov/33527395</a></p></li><li><p>Yang, SI, et al., &amp; Lee, SY (2004). Transdermal eperisone elicits more potent and longer-lasting muscle relaxation than oral eperisone. <i>Pharmacology</i> 71(3) 150–156. DOI:<a href=\"https://doi.org/10.1159/000077449\">10.1159/000077449</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15161997/\">https://pubmed.ncbi.nlm.nih.gov/15161997</a></p></li><li><p>Melilli, B, et al., &amp; Drago, F (2011). Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry. <i>European journal of drug metabolism and pharmacokinetics</i> 36(2) 71–78. DOI:<a href=\"https://doi.org/10.1007/s13318-011-0034-0\">10.1007/s13318-011-0034-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21448778/\">https://pubmed.ncbi.nlm.nih.gov/21448778</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M03BX09;
